胃癌免疫治疗临床研究进展  

Advances in clinical research of gastric cancer immunotherapy

作　　者：丁乃清 魏嘉[1] 陈仿军[1] 苏舒[1] 刘宝瑞[1] DING Nai-qing;WEI Jia;CHEN Fang-jun;SU Shu;LIU Bao-rui(the Comprehensive Cancer Centre of Drum Tower Hospital,Medical School of Nanjing University ＆ Clinical Cancer Institute of Nanjing University,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院肿瘤中心南京大学临床肿瘤研究所,南京210008

出　　处：《肿瘤综合治疗电子杂志》2018年第2期1-5,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家重点研发计划专项经费项目(2017YFC1308900);重大新药创制(2018ZX09301048-003)

摘　　要：胃癌发病率高、预后差,缺乏有效的治疗方法。近年来,肿瘤免疫治疗取得了突破性进展,为肿瘤治疗带来了革命性改变,也给恶性肿瘤患者带来了新希望。目前,程序性死亡蛋白1(programmed cell death protein 1,PD-1)/程序性死亡蛋白配体1(programmed death-ligand 1,PD-L1)单抗已被获批用于胃癌的治疗,多项肿瘤疫苗、过继性细胞疗法治疗胃癌的临床试验也在进行中,本文对胃癌免疫治疗临床研究进展进行综述。Gastric cancer is a malignant disease with high incidence, poor prognosis and is short of effective treatment. In recent years, cancer immunotherapy has made significant progress, revolutionized the cancer treatment paradigm and offered new hope for patients with malignancy. Monoclonal antibody targeting programmed cell death protein 1 （PD-1）/programmed death-ligand 1 （PD-L1） has been approved for the treatment of gastric cancer. Besides, many clinical trials of cancer vaccines and adoptive cell immunotherapy for the treatment of gastric cancer are in progress. Here, we review the clinical research progress of gastric cancer immunotherapy.

关 键 词：胃癌 免疫治疗 程序性死亡蛋白1/程序性死亡蛋白配体1单抗 过继性细胞疗法 肿瘤疫苗 

分 类 号：R735.2[医药卫生—肿瘤]